MDGL - NASDAQ
Madrigal Pharmaceuticals, Inc.
$488.15
+7.8%Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
At a Glance
Live SnapshotMadrigal Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Madrigal Pharmaceuticals, Inc. Income Statement
MDGL • NASDAQ
| Madrigal Pharmaceuticals, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
958.4M | 180.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.6M | 14.8M | 144.2M | 2.6M | 743K | 0.0 | |
GROSS PROFIT | ||||||||||||||||||||
(56.1M) | (6.2M) | (0.0) | (0.0) | (0.0) | (471K) | (112K) | (96K) | (77K) | (156.0) | (0.0) | (673K) | (516K) | (738K) | (1.5M) | (0.0) | (0.0) | (0.0) | (0.0) | (3.7M) | |
902.3M | 173.9M | 0.0 | 0.0 | 0.0 | -471K | -112K | -96K | -77K | -156.0 | 0.0 | -673K | -516K | -738K | 6.1M | 0.0 | 0.0 | 0.0 | 0.0 | -3.7M | |
OPERATING INCOME | ||||||||||||||||||||
(1.2B) | (671.8M) | (380.5M) | (293.6M) | (242.5M) | (205.8M) | (94.9M) | (40.4M) | (31.8M) | (25M) | (3.2M) | (83.3M) | (87M) | (60.4M) | (51.6M) | (49.8M) | (61.2M) | (96.1M) | (63.6M) | (55.5M) | |
(813.8M) | (435.1M) | (108.1M) | (48.1M) | (37.3M) | (21.9M) | (22.6M) | (15M) | (7.7M) | (9.3M) | (13.4M) | (15.7M) | (15.7M) | (11.7M) | (11.6M) | (11.4M) | (12.7M) | (14.7M) | (14.9M) | (8.6M) | |
(388.5M) | (236.7M) | (272.4M) | (245.4M) | (205.2M) | (184.8M) | (72.3M) | (25.4M) | (24.4M) | (15.9M) | (54.2M) | (68.2M) | (71.9M) | (49.4M) | (41.5M) | (40.3M) | (51.1M) | (81.6M) | (52M) | (50.5M) | |
-300.1M | -497.9M | -380.5M | -293.6M | -242.5M | -206.3M | -95M | -40.5M | -31.9M | -25M | -3.2M | -84M | -87.6M | -61.1M | -45.4M | -36.9M | 80.5M | -93.7M | -66.2M | -59.2M | |
PRE-TAX INCOME | ||||||||||||||||||||
(22.3M) | (14.7M) | (12.7M) | (4M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (1.2M) | (1.1M) | (2.2M) | (2.6M) | (1.8M) | (1.9M) | (569K) | (312K) | (489K) | (0.0) | (0.0) | |
15.1M | 32M | 6.9M | -1.8M | 363K | 4.3M | 11M | 7.7M | 558K | -1.2M | -3.6M | -2.2M | -2.6M | -1.8M | -1.9M | -569K | -216K | 1.1M | 2.7M | 1.9M | |
11.8M | 32M | 6.9M | -1.8M | 636K | 4.1M | 11M | 7.6M | 732K | -1.4M | -3.7M | -2.2M | -2.6M | -1.7M | -1.9M | -569K | -1.5M | 1.1M | 2.7M | 1.9M | |
-288.3M | -465.9M | -373.6M | -295.4M | -241.8M | -202.2M | -83.9M | -32.8M | -31.2M | -26.4M | -68.7M | -86.2M | -90.2M | -62.8M | -47.4M | -37.5M | 79.1M | -92.6M | -63.5M | -59.1M | |
NET INCOME | ||||||||||||||||||||
-288.3M | -465.9M | -373.6M | -295.4M | -241.8M | -202.2M | -83.9M | -32.8M | -31.2M | -26.4M | -6.8M | -86.2M | -90.2M | -62.8M | -47.4M | -37.5M | 79.1M | -92.6M | -63.5M | -57.3M |
SEC Filings
MDGL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 22, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 30, 2026 | January 29, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 11, 2025 | December 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your MDGL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.